AbbVie (ABBV) announced plans to launch ELAHERE in the U.K. at a list price equal to the U.S. AbbVie is in discussions with the National Institute for Health and Care Excellence to ensure that ELAHERE is valued fairly. The company noted that the value given to ELAHERE will determine the ability to launch in the U.K.
The European Commission granted approval of ELAHERE in November 2024 and was granted full FDA approval in the U.S. in March 2024. In July, the Medicines and Healthcare products Regulatory Agency approved ELAHERE.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.